EASTERN PEDIATRIC ONCOLOGY CONSORTIUM

东方儿科肿瘤学联盟

• 批准号: 2856407
• 负责人: Jeffrey M Lipton
• 金额: $ 6.27万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-05-20 至 2000-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2856407
• 关键词: 6 thiopurine; Ewing's tumor; Hodgkin's disease; Wilms' tumor; XomaZyme; acivicin; acute leukemia; acute lymphocytic leukemia; acute myelogenous leukemia; adolescence (12-20); antineoplastics; asparaginase; astrocytoma; biological response modifiers; bone marrow transplantation; brain neoplasms; cancer registry /resource; cancer risk; central nervous system neoplasms; child (0-11); chronic myelogenous leukemia; cis platinum compound; clinical research; clinical trial phase I; colony stimulating factor; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; cyclosporines; cytosine arabinoside; daunorubicin; deferoxamine; deoxycoformycin; doxorubicin; drug screening /evaluation; enalapril; ependymoma; etoposide; fazarabine; fluorouracil; germ cell neoplasms; glioma; hepatoblastoma; hepatocellular carcinoma; human genetic material tag; human immunodeficiency virus 1; human subject; human therapy evaluation; human tissue; ifosfamide; interferons; interleukin 2; medulloblastoma; melphalan; metastasis; methotrexate; mitoxantrone; molecular oncology; neoplasm /cancer chemotherapy; neoplasm /cancer classification /staging; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer immunology; neoplasm /cancer immunotherapy; neoplasm /cancer pharmacology; neoplasm /cancer radiation therapy; neoplasm /cancer relapse /recurrence; neoplasm /cancer surgery; neuroblastoma; nonHodgkin's lymphoma; osteosarcoma; paclitaxel; pediatric pharmacology; podophyllin; prednisone; retinoate; rhabdomyosarcoma; tissue resource /registry; topotecan; trimetrexate; vincristine

The Eastern Pediatric Oncology Group Consortium (EPOC) consisting of the Division of Pediatric Hematology/Oncology of the Mount Sinai School of Medicine (MSSM), Yale University School of Medicine (YUSM), University of Maryland School of Medicine (UMSM), and University of Massachusetts Medical School (UMMS) formalizes a long standing intellectual relationship between the Principal Investigators of the four institutions. The rationale for the existence of EPOC rests upon the expectation that our four institutions working together within POG will contribute more to the group than would occur if we continued to function separately. The long term objectives of the group are to make use of our scientific expertise in basic and clinical pharmacology, flow cytometry, cellular and molecular biology of neuroblastoma and bone marrow transplantation. Specifically, we will (l) develop and participate in new biologically based therapeutic approaches to neuroblastoma and other embryonal tumors of children. Specific pilot studies will include a phase I study of Gallium Nitrate, a phase I Study of 9-cis retinoic acid and novel cell cycle based therapeutic approaches to neuroblastoma involving chemosensitization with growth factor antagonists. (2) enhance minority participation in POG studies and in particular phase I studies. (3) continue to provide leadership in POG in the areas of pharmacology, neuroblastoma, bone tumors, bone marrow transplantation and non-Hodgkin's lymphoma (4) participate in the administrative functions of POG in the areas of bone marrow transplantation, new agents and pharmacology and non-Hodgkin's lymphoma.

东部小儿肿瘤集团（EPOC）由 小儿血液学/西奈山学校肿瘤学系 耶鲁大学医学院（YUSM）医学（MSSM），大学 马里兰医学院（UMSM）和马萨诸塞大学 医学院（UMMS）正式的长期知识分子 四个主要研究人员之间的关系 机构。 EPOC存在的理由取决于 期望我们的四个机构在POG中共同努力 对小组的贡献超过我们继续运作的情况 分别地。小组的长期目标是利用我们 基本和临床药理学方面的科学专业知识，流式细胞术， 神经母细胞瘤和骨髓的细胞和分子生物学 移植。具体来说，我们将（l）开发和参与新的 基于生物学的神经母细胞瘤和其他治疗方法 儿童的胚胎肿瘤。特定的试点研究将包括一个阶段 我研究了硝酸盐，一项对9盘视黄酸和 基于细胞周期的新型神经母细胞瘤的治疗方法涉及 与生长因子拮抗剂的化学敏化。 （2）增强少数民族 参与POG研究，特别是I期研究。 （3） 继续在药理学领域的POG领导， 神经母细胞瘤，骨肿瘤，骨髓移植和非霍奇金的 淋巴瘤（4）参与POG的行政职能 骨髓移植，新药理学和药理学领域 非霍奇金的淋巴瘤。